Figure S1. BALB/c donor mice were immunized with diluent or B6 BM derived CD8α⁺ DC or CD8α⁻ DC as in methods
Splenic T cells from them were harvested and cultured for 72 hours with syngeneic or allogeneic irradiated (3,000cGy) splenocytes (2 × 10⁵ or 1 × 10⁵/well) from WT B6 and analyzed for (A) proliferation and (B) INF-γ. * P < 0.05 between T cells from diluent treated animals vs. those immunized with CD8α⁺ DCs. Data are from 1 of 3 similar experiments.

Figure S2. BALB/c donor mice were immunized with diluent or B6 BM derived CD8α⁺ DC or CD8α⁻ DC as in methods
Splenic T cells from them were harvested and used as donor T cells along with WT BM in allo-BMT into lethally B6 hosts as above. Small and large bowels and livers were harvested on day 21 after BMT and scored semi quantitatively to assess pathologic damage. * P < 0.05 between recipients of T cells from diluent or CD8α⁻ DCs immunized BALB/c donors vs. the CD8α⁺ DCs vaccinated donors.

Figure S3. CD8⁺ DC vaccination preserves sufficient alloreactivity for induction of GVL.
C3H.sw donor mice were immunized with host B6 BM derived CD8α⁺ DC or CD8α⁻ DC (2–3 × 10⁵ cells/vaccination) at days −8, −5 to −3, and −1 as described in Material and Methods. On day 0, 50,000 MBL-2 cells were injected to each recipients along with syngeneic (B6) or allo-genic (C3H.sw) BM and either B6 or C3H.sw CD90⁺ splenic T cells. Animals were monitored twice daily for survival and the cause of death determined by postmortem gross pathology examination. P=NS between all three allo-groups.
Figure S1

A

[CMP (x10^4)]

P<0.0001

P<0.0001

P=0.003

Syngeneic  BALB/c WT

B

IFN-γ

P=0.01  P<0.005

BALB/c B6-CD8^+DC vaccinated  BALB/c B6-CD8-DC vaccinated
Figure S2

Pathological score (day 21)
Figure S3

![Graph showing percent death after BMT](image)

Legend:
- B6+MBL-2 50,000→B6 (n=6)
- C3H.sw+MBL-2 50,000→B6 (n=8)
- C3H.sw (CD8^+DC)+MBL-2 50,000→B6 (n=8)
- C3H.sw (CD8^DC)+MBL-2 50,000→B6 (n=8)